Myco

Quick links to important sections

Myco

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Myco

Quick Facts: Myco (Ketoconazole)

Property Description
Active Ingredient Ketoconazole
Form Tablet, cream, shampoo
Pharmacological Class Antifungal agent (Azole derivative)
General Purpose To halt and reverse fungal proliferation
Origin Synthetic drug

Defining the Antifungal Agent

The medicine Myco is the reference name for a pharmaceutical product containing the active ingredient Ketoconazole, a synthetic drug designed to combat fungal growth. It is officially classified as an antifungal agent and falls into the azole antifungal group, specifically an imidazole derivative. This means the medicine is manufactured solely as an antimycotic drug to address problems caused by pathogenic fungi and yeast, making it distinct from treatments for bacterial or viral conditions. Ketoconazole's long history of clinical use has established its recognition across global pharmacological studies.

The compound is typically utilized as a single-ingredient product, available in multiple dosage form(s). These include an oral medication (tablet) for systemic treatment and various topical preparations such as a cream or shampoo for localized action. This dual availability is a differentiating factor, allowing flexibility in prescribing based on the site and extent of the issue.

Mechanism and General Purpose

The general purpose of this broad-spectrum antifungal agent is to halt and reverse the proliferation of fungi by targeting a vital structure in the fungal cell. The drug works by interfering with ergosterol synthesis, causing structural damage to the fungal cell membrane.

As an antifungal, Ketoconazole's action is primarily fungistatic and fungicidal. The drug's overarching function is the systematic control and reduction of the pathogenic fungal population by preventing its survival and proliferation. For instance, in its shampoo form, the product is commonly employed to manage scalp conditions where fungal overgrowth is a primary factor. Whether administered orally or topically, the core goal remains the same: to stop the fungal issue at its source.

Regulatory References

  1. MedlinePlus: Ketoconazole Overview
  2. NIH/PubMed: Imidazole Antifungal Mechanism
  3. European Medicines Agency (EMA)

What side effects are possible with Myco?

Official Safety Profile and Adverse Reactions

The medicine Myco, which contains Ketoconazole, has a safety profile that is explicitly differentiated by its form of administration. Regulatory documents establish that the oral tablet carries a greater risk profile than the topical forms (cream or shampoo).

Serious adverse reactions for the systemic oral tablet are documented across major physiological systems, with the most significant being the risk of severe, potentially fatal Hepatotoxicity (Liver Injury). This risk is prominent enough to warrant a Boxed Warning in the U.S. labeling. Other serious concerns include Adrenal Insufficiency, which results from the inhibition of adrenal corticosteroid secretion, and the potential for life-threatening Ventricular Arrhythmias (Torsades de pointes) when co-administered with certain contraindicated medicines. These serious events are often reported from post-marketing surveillance and have a frequency classification of Not Known.

Less serious but more commonly reported adverse reactions for the oral tablet are often categorized as Gastrointestinal Complaints, including nausea and vomiting.

Population-Specific Constraints

Official labeling defines specific constraints for certain populations. The oral tablet is contraindicated in individuals with pre-existing acute or chronic liver disease. Safety and efficacy have not been established in pediatric patients under the age of two for some formulations.

Topical Safety Notes

Regulatory assessments clarify that the topical formulations (cream and shampoo) have not been associated with the severe systemic risks, such as major liver damage or adrenal problems, seen with the oral tablet. Adverse reactions associated with topical use are typically localized, including pruritus, dry skin, or a burning sensation at the site of application. The safety documentation focuses heavily on the systemic risks of the oral form.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documentation defines the Ketoconazole overdose profile by its potential for serious systemic toxicity, primarily affecting hepatic, endocrine, and cardiovascular function. When over-ingestion is suspected, regulatory authorities mandate urgent medical contact, advising patients to seek immediate medical attention or contact a poison control center.

Documented Overdose Manifestations and Risks

Category Official Regulatory Entities
Documented Manifestations Acute liver injury, nausea, anorexia, fatigue, and jaundice (yellowing of skin/eyes).
Severe Outcomes Serious hepatotoxicity (potentially leading to fatal outcomes or liver transplantation), adrenal insufficiency, and risk of life-threatening ventricular dysrhythmias such as Torsades de Pointes.

Emergency Actions and Management

No specific antidote is known for Ketoconazole overdose. Management is symptomatic and supportive. Official procedures state that gastric lavage and activated charcoal may be used only if administered within one hour of ingestion. Due to the high-risk profile, close monitoring of the patient's blood pressure and fluid/electrolyte balance over several days is required. Patients should seek medical attention right away if they experience signs of liver problems, such as unusual fatigue or dark urine, as these signal the drug's most serious documented complication.

Therapeutic Uses of Myco

Myco is commonly used to help address infections caused by a fungus or yeast, addressing symptoms that create noticeable physiological strain. The medicine generally provides supportive relief in contexts where additional symptomatic support is needed.

It is considered relevant for managing conditions characterized by periods of heightened symptoms, specifically seborrheic dermatitis and chronic dandruff, which are conditions involving recurrent or episodic manifestations related to fungus. It is also commonly applied in acute scenarios to manage superficial mycoses, including ringworm, athlete's foot, and oral thrush. For serious conditions, it is applied in clinical settings that involve acute or unstable symptom patterns, being relevant for severe, deep-seated fungal infections like blastomycosis and histoplasmosis.

“The goal is to apply management that helps reduce the overall burden of symptoms, assisting with maintaining functional stability during symptomatic periods.”

Therapeutic Focus Areas

This medication is applied across domains where additional symptomatic support is needed, primarily focusing on Controlling Fungal Skin and Mucosal Infections and Managing Chronic Scalp and Skin Overgrowth. This support helps ease symptoms that relate to systemic imbalance.


Quick Fact: Relief for Pruritic Discomfort
Myco is commonly used to help address the intense itching (pruritus), scaling, and flaking that are commonly associated with fungal infections and seborrheic conditions. It contributes to improved day-to-day comfort.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Official Eligibility for Myco (Ketoconazole) Use

The eligibility profile for Myco is defined by regulatory documents that strictly distinguish between its systemic (oral tablet) and localized (topical) formulations. Use of the oral tablet is contraindicated in several population groups, including patients with acute or chronic liver disease or a current or history of hepatitis.

The oral tablets are also contraindicated in children and adolescents under 18 years of age and in pregnant women. Systemic use is restricted to adult patients only when alternative antifungal therapies have failed or are deemed inappropriate. Additionally, patients with known hypersensitivity to ketoconazole must not use any formulation.


Population Eligibility Oral Tablets (Systemic) Topical Forms (Localized)
Children/Adolescents Contraindicated (Under 18) Approved (12 years of age and older)
Pregnancy Contraindicated Permitted
Liver Disease Contraindicated Permitted
Renal Impairment Permitted Permitted

For breastfeeding women, the oral tablet is not recommended. However, due to limited systemic absorption, topical forms (cream and shampoo) may be used during both pregnancy and lactation, as documented in official regulatory labeling.

What should I know about interactions with other medicines?

Mycophenolic acid (Myco) is subject to several significant interactions, primarily affecting its blood concentrations, which is critical for maintaining its desired effect. These interactions are largely pharmacokinetic, involving changes in absorption or metabolism. Co-administration is generally not recommended with agents that reduce Myco levels, including antacids containing magnesium and aluminum hydroxides, bile acid sequestrants like Cholestyramine, or phosphate binders such as Sevelamer. These products can decrease Myco absorption or interfere with its enterohepatic recirculation.

Concomitant use with Azathioprine is not advised due to competing actions on purine metabolism. Certain broad-spectrum oral antibiotics, such as Norfloxacin and Metronidazole, may reduce Myco levels by interfering with the enterohepatic recirculation; combined use is typically discouraged. Strong enzyme inducers like Rifampin may significantly decrease Myco concentrations and should be avoided or used with great caution.

When Myco is combined with drugs excreted via renal tubular secretion, such as Acyclovir or Ganciclovir, the concentrations of both drugs may increase, requiring careful monitoring. Hormonal contraceptives may have reduced effectiveness when taken with Myco; additional barrier contraception is required to ensure prevention of pregnancy.

Mechanism of Action

How Myco Works

Myco exerts its primary action by selectively engaging key regulatory receptor systems in central and/or peripheral pathways. This initial interaction is a form of modulation that adjusts the receptor's responsiveness to the body's natural signaling molecules, which precedes subsequent cellular effects.

Following receptor engagement, the drug operates within intracellular signal transduction pathways. Myco modifies early molecular steps, thereby initiating or suppressing specific signaling sequences that lead to downstream cellular effects. This action alters the signaling dynamics inside the cell, where targeted pathway adjustment is required.

The mechanism of action influences core regulatory systems, resulting in the modulation of signaling patterns. By dampening excessive activity in specific neural or humoral pathways, Myco causes a reduction in the effect of specific mediators and alters activity patterns in affected pathways. This influence on core mechanisms is responsible for the overall effect profile.

Dosage and Administration Information

How Myco is Used: Official Administration and Dosing

The use of Myco (Ketoconazole) is governed by its official route of administration and dosage form, with specific regimens established for clinical use. The medicine is available for both systemic and localized application.


Official Administration Instructions

Administration Scope Administration Details
Route of administration Oral (Tablet) for systemic use; Topical/Cutaneous (Cream, Shampoo, Gel, Foam) for localized action.
Standard Adult Dosing Oral: 200 mg once daily (qd) initially for systemic fungal infections, potentially increased to 400 mg qd. For endocrine use, starting doses range from 400 mg to 600 mg daily in divided doses.
Topical Dosing Cream 2%: Applied once daily or twice daily depending on the condition. Shampoo 2%: Typically used twice weekly for 2 to 4 weeks for seborrheic conditions.
Timing in relation to meals Oral Tablets must be taken with food to maximize absorption.
Pediatric Rules Oral: Weight-based dosing (3.3 to 6.6 mg/ kg qd) for children aged 2 years and older.
Duration of Treatment Varies by route; topical treatment ranges from 2 to 6 weeks. Oral treatment continues until clinical clearing.

Key Procedural Constraints

These instructions define the standardized approach to administration:

  • Oral: Tablets must be ingested with food. In cases of low stomach acidity, the protocol includes steps for dissolving the tablet in an acidic solution prior to ingestion.
  • Topical: Cream, foam, and shampoo preparations are strictly for external use only and are not to be applied to the eye, mouth, or other internal areas. The 2% shampoo requires the user to lather and leave the product in place for a specified time (e.g., 5 minutes) before rinsing.
  • Use Restriction: Oral administration of Ketoconazole is restricted in patients with liver disease.

Recent Clinical Evidence

Evidence for Topical Use in Chronic Skin Conditions

Research has focused extensively on the topical form of Myco (Ketoconazole) for conditions characterized by fluctuating or episodic manifestations, such as chronic dandruff and seborrheic dermatitis. This evidence comes primarily from short-term Randomized Controlled Trials (RCTs) and systematic reviews applied in studies examining patient-reported experiences. Researchers measured outcomes related to physical discomfort, such as the scaling, flaking, and intensity of itching (pruritus), and also monitored mycological clearance (reduction of Malassezia yeast).

Trials consistently reported patterns observed where the measured decrease in the fungal count was associated with a measured decrease in symptoms. However, long-term outcomes are not fully established, and there is limited information regarding how continuous use might affect the condition over several years. Follow-up durations were limited in most primary trials.


Research on Topical Treatment of Superficial Fungal Infections

The topical formulation was studied for managing common superficial mycoses, like ringworm and athlete's foot. This evidence relies on numerous short-term Comparative Trials that examined clinical cure rate and mycological cure rate (whether the fungus was eradicated). Studies reported that a specific percentage of participants achieved the study endpoint of mycological cure concurrently with the resolution of physical lesions.

While the short-term clearance rate is measurable, the follow-up durations were limited, meaning the research provides limited insight into how often the infection recurs after several months or a year. Comparative evidence is lacking against the full range of alternative treatments, and results apply only to the specific populations studied.


Evidence Gaps and Areas of Scientific Uncertainty

The research contributes to the broader evidence landscape, but some key areas of uncertainty remain. The evidence quality varies across studies, and many foundational studies for systemic use rely on modest sample sizes and older methodologies. Long-term effects are not fully established, particularly regarding the durability of symptom control and recurrence rates over several years.

Frequently Asked Questions (FAQ)

Common questions about Myco (FAQ)

Q: Is Myco a prescription medication, or can it be bought over-the-counter?

A: The oral tablet form of Myco (Ketoconazole) is strictly a prescription-only medication in the United States. While some lower-strength topical forms, such as certain creams and shampoos, may be available over-the-counter, the systemic oral tablet requires a prescription.

Q: How quickly does Myco start working after the first dose?

A: Official pharmacological documents describe the rate at which the active ingredient enters the bloodstream. After a single oral dose taken with food, the mean peak plasma levels of the active ingredient are generally reached within 1 to 2 hours.

Q: How long does the effect of a single dose of Myco typically last?

A: The body processes the active ingredient in two phases. The time it takes for the concentration to reduce by half (half-life) is initially about 2 hours, and later transitions to approximately 8 hours.

Q: Do I need to change my diet while taking Myco?

A: Official administration instructions indicate that the oral tablets are generally taken with food to support maximum absorption of the medicine. The drug label does not, however, mandate a specific diet change outside of this timing requirement.

Q: Are there any specific foods that should be avoided when using Myco?

A: Regulatory documents describe a constraint where patients taking oral Myco are advised to avoid consuming alcohol during treatment. This caution is stated because the combination of the medicine and alcohol may potentially increase the risk of liver damage (hepatotoxicity).

Q: Can Myco cause long-term health issues?

A: Official warnings note that oral Myco has been associated with serious hepatotoxicity (liver injury), including cases that were fatal or required liver transplantation. This risk is reported to occur in patients receiving the medicine for both short and long durations of treatment.

Q: Are the side effects of Myco usually temporary?

A: While common, less serious side effects are often temporary. The most severe adverse reaction is liver injury (hepatotoxicity), which has been reported as reversible in most cases upon stopping the medicine, although reversibility is not guaranteed.

Q: How long can a person safely stay on Myco?

A: The duration of treatment is variable and depends on the specific infection being treated, sometimes lasting six months or longer until a cure is achieved. Due to the risk of serious side effects, the continuation of treatment is generally restricted and requires ongoing clinical monitoring.

Q: Does Myco interact with common pain relievers like ibuprofen or acetaminophen?

A: The potential for drug-drug interaction exists when oral Myco is used concurrently with other medications that are potentially hepatotoxic (harmful to the liver). Since some common pain relievers, such as acetaminophen, carry a known risk of liver damage, this combination may potentially increase the risk of liver injury.

Q: Can Myco be crushed or split if someone has trouble swallowing pills?

A: Official regulatory documents indicate that the tablets are taken whole. However, the label does detail a specific procedure for preparing the tablet in an acidic solution for patients with low stomach acidity, as this may be necessary to support absorption.

Q: Why do doctors prescribe Myco over other available treatments?

A: Oral Myco is highly restricted by regulatory agencies due to its risk profile. Official guidance states it should only be used for certain serious fungal infections when alternative antifungal therapies are unavailable or cannot be tolerated by the patient.

Q: Can Myco be taken if a person has a history of heart issues?

A: Regulatory documents describe that oral Myco is contraindicated for individuals who have certain heart conditions. These conditions include congestive heart failure, a slow heartbeat, or a personal or family history of QTc prolongation or sudden cardiac death.

Q: What is the difference in how Myco works compared to a placebo in trials?

A: Clinical trials for superficial infections measured effectiveness using quantifiable outcomes compared to a non-active substance (placebo). These included the mycological cure rate (fungus eradication) and clinical cure rate (symptom resolution), which were achieved in a specific percentage of participants receiving the active drug.

Q: What happens if Myco is taken at the wrong time of day?

A: Regulatory documents indicate the drug should be taken with food to achieve its maximum absorption and effectiveness. Taking it without food could lead to lower-than-intended levels of the medicine in the blood, potentially reducing its intended effect.

Q: Does Myco contain any gluten or common allergens?

A: Regulatory documents list the inactive ingredients (excipients) in the oral tablets, which can include substances like lactose monohydrate and corn starch. A complete review of the official ingredient list for the specific product formulation is needed for patients with known allergies or sensitivities.

Q: Is it normal to feel a little dizzy or lightheaded when starting Myco?

A: While not listed among the most common adverse reactions, feelings of dizziness or lightheadedness have been reported. Such occurrences are important safety signals described in the official warnings and may require clinical evaluation.

Q: Can Myco affect the results of laboratory tests?

A: Yes, laboratory tests are required for monitoring. Regulatory labeling mandates the monitoring of liver function tests (such as ALT and AST) and adrenal function to detect any potential adverse effects of the drug while in use.

Q: Can Myco affect my mood or cause emotional changes?

A: Mental and mood changes have been reported as serious side effects with oral Myco. This includes specific events such as depression or, in rare instances, thoughts of suicide.

Q: What should I do if I notice a skin rash after starting Myco?

A: A rash is a reported safety signal associated with serious conditions, including both hepatotoxicity and severe allergic reactions (hypersensitivity). This symptom may require immediate clinical evaluation, especially when accompanied by other severe symptoms.

Q: How long after stopping Myco is it out of the system?

A: Pharmacokinetic data shows the active ingredient's terminal half-life is 8 hours. The elimination time is determined by this rate, as it takes approximately five half-lives for the concentration to become negligible.

Q: Is Myco available as a generic medicine?

A: Yes, the oral tablet formulation of Myco, which contains the active ingredient Ketoconazole, is officially available as a generic medicine.

Q: What is the regulatory status of Myco in major countries outside the US?

A: The regulatory status varies significantly outside the U.S. In the European Union, the European Medicines Agency (EMA) recommended the suspension of oral tablets in 2013 due to liver toxicity concerns. Similarly, in Canada, the drug's approved uses were restricted in 2013 to only serious systemic fungal infections.

Q: What are the signs that Myco is starting to work for the intended purpose?

A: For topical uses, clinical studies measured effectiveness by observing positive changes in key symptoms. These signs included a measured decrease in physical symptoms like scaling, flaking, and the intensity of itching, coupled with a positive result for mycological clearance (reduction of the fungus).

Q: Does Myco affect your ability to drive or operate machinery?

A: Some reported side effects may potentially affect attention and motor skills. Adverse reactions such as dizziness or mental/mood changes could impair a person’s ability to safely operate a vehicle or heavy machinery.

How should Myco be stored and disposed of?

Store Myco (Doxycycline/Minocycline) oral forms in the original container, tightly closed, at controlled room temperature (68°F to 77°F or 20°C to 25°C). The medication must be kept away from light, excess heat, and moisture; avoid storing it in the bathroom. The oral suspension must be discarded after two weeks. All forms must be stored out of the reach and sight of children and pets in a secure location. Do not use expired medicine, as decomposed tetracyclines can cause serious illness.

For disposal, the best option is to use a drug take-back location or a prepaid mail-back envelope. If these are unavailable, check the FDA's flush list; if not listed, mix the medicine with an undesirable substance (e.g., used coffee grounds), place the mixture in a sealed bag or container, and discard it in the household trash. Do not pour or flush medicine down the drain unless specifically instructed.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Myco found in:

A-Z Index: